# Application Form for EuroMRD Membership

# ALL, MLL and/or lymphoma section

#### (For background information: see guidelines for EuroMRD membership d.d. June 2010)

Name :

Department :

Institute :

Address :

E-mail :

Phone :

Fax :

## I wish to become member of:

EuroMRD ALL section

EuroMRD MLL section

EuroMRD Lymphoma section

## **A. Extensive knowledge on Ig/TCR gene rearrangements**

YES NO

1. Structure and composition of all seven human Ig/TCR genes
2. Immunobiology of Ig/TCR gene rearrangements     
   (recombinase system, stepwise process, Ig class switch
3. Repertoire of rearranged Ig/TCR genes     
   (combination repertoires, junctional regions, somatic   
   hypermutation process, antigen selection processes)
4. Ig/TCR gene rearrangement patterns in normal and malignant lymphoid cells

## **B. Extensive experience in MRD detection via Ig/TCR gene rearrangements or other patient-specific PCR targets at the DNA level**

###### Detection and identification of Ig/TCR gene rearrangements

YES NO YES NO

* *IGH*   − *TCRB*
* *IGK*   − *TCRG*
* *IGL*   − *TCRD*

###### Detection and identification of other MRD-PCR targets at DNA level

YES NO YES NO

* *TAL1*   − *BCL1*
* *MLL*   − *BCL2*
* Other:  − Other:

###### Applied methods for detection and identification of MRD-PCR targets at DNA level

YES NO YES NO

* Southern blotting  − GeneScanning
* PCR  − heteroduplex analysis
* LM-PCR   − sequencing of junctional regions
* Other:  − Other:

###### Applied RQ-PCR technology

YES NO

* Hydrolysis probe (TaqMan) technology
* Hybridization probe (LightCycler) technology
* SYBR Green I technology
* Other:

###### Applied RQ-PCR targets

YES NO Estimated % of all targets

* *IGH* (VH-JH and DH-JH)         %
* *IGK* (Kde and Vκ-Jκ)         %
* *IGL*          %
* *TCRB* (Vβ-Jβ and Dβ-Jβ)         %
* *TCRG*         %
* *TCRD* (Vδ-Jδ, Dδ-Jδ, Vδ2-Dδ)         %
* *TAL1*         %
* *MLL*         %
* *BCL1*         %
* *BCL2*         %
* other:               %
* other:               %

###### **Level of experience with RQ-PCR-based MRD diagnostics**

* RQ-PCR-based MRD diagnostics since (year):
* MRD diagnostics according to EuroMRD guidelines: YES: NO:
* Trained by/collaboration with:
  + name of EuroMRD laboratory:
  + responsible scientist (name):
* No. of patients completely analyzed (including two follow-up time points):       (at least 25 cases)
* No. of patients analyzed and approved in full parallel to the above   
  mentioned EuroMRD laboratory:        (at least 5 cases)
* Own publications in the field of MRD diagnostics (if available):

## **C. Position of MRD laboratory: size, relation to (inter)national treatment protocols, and annual intake of new patients**

###### Size of MRD laboratory

* No. of scientists:       (at least one)
* No. of technicians:       (at least two)

###### Position of MRD laboratory at national level

Acting as central MRD laboratory for the following MRD-based treatment protocol(s):



###### Annual intake of new patients with complete MRD diagnostics:

**Protocol Patients Non-Protocol Patients**

* childhood ALL:
* infant ALL:
* adult ALL:
* relapsed ALL\*:
* other:             +       +

Total:             (at least 50 to 60 new Protocol Patients per year)

\* A relapsed ALL patient can be regarded as a new patient, if MRD is monitored after relapse

## **Approved by:**

Supervisor / head Chairman of MRD-based Collaborating EuroMRD  
of MRD laboratory treatment protocol laboratory

…………………………… ………………………………… …………………………………  
signature signature signature

…………………………… ………………………………… …………………………………

name name name

…………………………… ………………………………… …………………………………

date date date

**Completed forms should be returned to:**

Dr. C. Eckert

Dept. of Pediatric Oncology and Hematology

Charité CVK

Universitätsmedezin Berlin

Mittelallee 6a, Pav 32, 1.OG

Augustenburger Platz 1

13353 Berlin

Germany

Email address: cornelia.eckert@charite.de